Alzheimer’s | OSU MedNet21

CME Webcast Teaches Learners About Alzheimer’s Disease. Expert Teaches on Artificial Intelligence in Medicine. This program will discuss Alzheimer’s Disease. This webcast will discuss new developments in our understanding of the pathogenesis and diagnosis of Alzheimer’s Disease. In addition, this webcast will review new treatments for Alzheimer’s Disease, including anti-amyloid monoclonal antibodies.

For more than a century, there was little physicians could do for patients with Alzheimer’s Disease other than diagnose it and provide supportive care. But during the past 2 years, new drugs have been approved by the FDA that appear to actually modify the progression of the disease. On this webcast, we’re going to update you on Alzheimer’s Disease. Joining us is Assistant Professor of Neurology, Dr. Arun Ramamurthy.

What you’ll learn on this webcast

As a result of this educational activity, webcast participants will be able to:

Describe Alzheimer’s Disease pathology
Discuss current medication options
Highlight Alzheimer’s Biomarkers
Future directions in diagnosis and treatment

You’ll also learn about the following:

Diagnosis of Alzheimer’s Disease
Treatment of Alzheimer’s Disease

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Webcast Producer at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.

Learn About Latest Discoveries in Alzheimer’s Disease on CME Webcast. 120 years ago, when Dr. Alzheimer first started taking care of Auguste Deter, there was no treatment for her condition. But now, medical research has brought us new treatments with hope for some patients who previously had no hope. On this CME webcast, we are going to hear about some of this research and some of these new treatments. We’re pleased to welcome Assistant Professor of Neurology, Dr. Rawan Tarawneh.

View a video introduction of this webcast

What you’ll learn in this webcast

As a result of this educational activity, webcast participants will be able to: Understand the pathology of Alzheimer disease, including the clinical and pathological heterogeneity and the importance of biomarkers for an accurate diagnosis; Learn about the new FDA-approved anti-amyloid agent aducanumab (approved June 2021).

You’ll also learn about the following:

Etiology of Alzheimer’s Disease
Alzheimer’s Disease treatments
Concerns regarding aducanumab
Identifying patients with Alzheimer’s disease in the primary care office
Diet and lifestyle measures
Managing insomnia

You can find this and many other MedNet21 programs on the OSU – CCME website.

Call our MedNet21 Program Manager at 614.293.3473 for more details about subscribing to MedNet21 as a hospital or as an individual. You can also e-mail him at derrick.freeman@osumc.edu.